Navigation Links
NeoStem, Inc. Comments on Recent Selling Pressure
Date:5/28/2008

NEW YORK, May 28 /PRNewswire/ -- Responding to the decline in NeoStem, Inc.'s (Amex: NBS) market capitalization during the past four trading days, Robin Smith, CEO, NeoStem said, "We know of no business development at the Company that would lead to the sudden decline in our share price."

Dr. Smith continued, "As announced on May 21, 2008, we received a private placement financing in a total amount of $900,000, which includes a strategic investment from the New England Cryogenic Center, Inc., one of the largest full-service cryogenic laboratories in the world and participation by management. These funds will be instrumental in executing on our plans to educate potential clientele about our services, especially in the Northeast." The private placement was of units with each unit priced at $1.20 and consisting of one share of common stock and a warrant to buy one share of common stock at $1.75 per share.

In addition, on May 27, 2008, NeoStem announced that an agreement had been signed with the University of Louisville Hospital's James Graham Brown Cancer Center to become a NeoStem collection center for adult stem cells. NeoStem has now signed its first agreement with a hospital to become a stem cell collection center and it believes this unique corporate and academic relationship will assist in propelling the adult stem cell field forward.

"We remain extremely excited by the growth prospects for NeoStem and are pleased to see the recent article written by Alan Boyle, Science Editor, MSNBC, entitled "Stem Cell Banks Could Pay Medical Dividends." The link reference is http://www.msnbc.msn.com/id/24797415/

About NeoStem, Inc.

NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission. Further, the Company cautions that its very small embryonic-like (VSEL) stem cell technology is in early stages of research and the reference to Alan Boyle's article is only intended to show the interest in stem cell banking generally and not to imply anything about the Company's products and services. The Company's further development is highly dependent on future medical developments and market acceptance which is outside its control.

Contact:

NeoStem, Inc.

Robin Smith, Chief Executive Officer

T: 212-584-4180

E: rsmith@neostem.com

http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lyme Lies: Allen Steeres horrifying comments regarding Lyme disease in last weeks commencement address
2. RNC RESPONSE TO OBAMA COMMENTS ON MEDICAL MARIJUANA LAWS
3. InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results
4. Xmark Comments on Genaera Cost-Saving Plan
5. Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
6. FRC Action Praises John McCains Pro-Life Comments
7. JAMA editor-in-chief comments on Pfizer lawsuit
8. Vital Images Comments on CMS Decision to Allow Local Coverage for Cardiac CT Angiography
9. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
10. MGT Comments on American Cancer Societys Decision to Endorse CT Colonography
11. URAC Invites Health Management Industry, Public for Comments on Changes to Its Core Accreditation Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Greenwich, Connecticut (PRWEB) , ... September 22, 2017 ... ... to conquering Lyme and other tick-borne diseases through research, education and awareness, today ... , A noted immunologist and microbiologist, Dr. Sellati has more than 20 ...
(Date:9/21/2017)... Angeles, CA (PRWEB) , ... September 21, 2017 ... ... a lunch and learn with Infinity Behavioral Health Services for professionals in the ... in a Commercial Payer Audit . , Insurance companies and state and ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... or exercise more try taking a more holistic approach and use natural alternatives ... Amazon essential oil collection is certified USDA guaranteeing that, the new line of ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction treatment ... a time when Virginia faces an opioid epidemic. , Last year, ... of 38 percent from 2015, underscoring the need for additional addiction treatment options. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery Center, a men-only ... The Joint Commission for chemical dependency and behavioral health services. , The Joint ... organizations that meet the commission’s rigorous standards. Accreditation by The Joint Commission is ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology: